Colorectal cancer is the third leading cause of cancer death in the United States. The American Cancer Society estimates that this year alone, 106,180 new cases of colon cancer will be diagnosed.
Two promising new studies have revealed that certain cannabinoids, including CBD, CBDV, CBG, CBGV and CBL, can suppress the growth of harmful colorectal cancer cells in humans. These studies offer some guiding light for those researching cannabinoids for the treatment of cancer, although they are limited in scope.
THC could not be included in the research group of either study due to regulations that do not allow certain scientists to study it. The “psychoactive” cannabinoid was left out. But studies indicate that the entourage effect with other cannabinoids like CBD, CBG and CBL working in concert helps propel the “anti-proliferative” effect. One of the studies even highlights the entourage effect with cannabinoids and mushroom extracts working together to shrink cancer cells.
Cannabotech’s integrative colon study eliminates 90% of cancer cells in model
A new product released in the US, UK and Israel in the fall of 2022 has been shown to eliminate over 90% of colon cancer cells in a cell model. The product, called Cannabotech Integrative-Colon, used a combination of non-psychoactive medicinal mushrooms and various cannabinoids to target colorectal cancer cells.
Cannabotech did not use psilocybin, the most common psychoactive mushroom, for this study. They also didn’t study THC, only other non-psychoactive cannabinoids. Today, there are over 100 known cannabinoids. I spoke with the study’s principal investigators, Professor Tami Peretz, a senior oncologist at Hadassah Ein Kerem Hospital, and Dr. Isaac Angel, a pharmacologist specializing in drug development, who further explained their findings. .
Which cannabinoids exactly were used in this Cannabotech Integrative-Colon study? Since Cannabotech plans to sell this formula, its exact percentages and dosages of each cannabinoid is restricted information. “THC was not included,” said study leaders Dr. Angel and Peretz. “The key ingredients were CBD and several other minor cannabinoids. We cannot divulge their names and composition, as this is part of our proprietary information.
The company decided not to study the effect of THC, pointing out the difficulty of its accessibility and regulation. “We have not studied THC and therefore cannot comment on its possible effects in this experimental setting,” they state. “We deliberately excluded THC from the product as it is the key psychoactive ingredient in cannabis and we wanted to avoid this effect in our preparation. All minor cannabinoids used are known and have no regulatory issues in their use.
Cannabotech aims to make this a peer-reviewed study in the future, its scientists tell me. “We are only at the beginning of our process and we are reporting our results in several types of colon cancer cell lines. We plan to extend the studies also to in vivo studies and finally publish them in a peer-reviewed journal,” say Dr. Angel and Peretz.
The duo say they didn’t use psilocybin, a common psychedelic mushroom, but rather “extracts from a mixture of known non-psychoactive edible mushrooms,” they say. “Indeed, we saw an interesting entourage effect not only when we compared the cannabinoids alone with the mixture, but also when we included the mushroom extract with the cannabis extract.”
A second study finds that cannabinoids can inhibit the growth of cancer cells in humans
A second study published recently by scientists from the Department of Nutrition and Food Science at the University of Maryland found that cannabidiol exerts “anti-proliferative activity” in colorectal cancer cells, meaning it stops their growth. .
The study states that its conclusions are threefold: “CBD suppresses the viability of human colorectal cancer cells; CBD induces cell cycle arrest and increases apoptosis and ER stress in human colorectal cancer cells; and CBD represses cell viability and induces apoptotic cell death via a CB2-dependent mechanism.
The cannabinoid receptor 2, part of our endocannabinoid system, is the receptor where this effect has been observed. This means that our CB1 receptors may not indicate the same effect, the “anti-proliferation” of these cancer cells in humans.
“Our data indicate that CBD and its derivatives may be promising agents for the prevention of human colorectal cancer,” the study researchers write. Scientists cited in this study include Hee-Seop Lee Gillian Tamia, Hee-Jung Song, Darshika Amarakoon, Cheng-I Wei, Seong-Ho Lee.
The study found that this “anti-proliferative activity” was also seen for other cannabinoids, including cannabidivarin (CBDV), cannabigerol (CBG), cannabicyclol (CBL), and cannabigerovarin (CBGV).